news
COVID-19 update: funding for treatments and vaccines
Drug Target Review rounds up the latest announcements regarding funding for research into COVID-19 treatments and vaccines.
List view / Grid view
US Food and Drug Administration (FDA)
news
FDA and BARDA to collaborate with Grifols on COVID-19 therapeutics
Grifols will leverage their resources to develop and test convalescent plasma-derived COVID-19 therapeutics in partnership with the FDA and BARDA.
article
Host pathways in coronavirus replication and COVID-19 pre-clinical drug target identification using proteomic and chemoinformatic analysis
The identification of host dependency factors mediating virus infection may provide key insights into effective molecular targets for developing broadly acting antiviral therapeutics against SARS-CoV-2 and other deadly coronavirus strains. Here, Joseph Steward highlights key findings of recent research.
news
Remdesivir most promising COVID-19 drug, say researchers
A review of potential COVID-19 therapeutics revealed that the most effective are likely to be those directly targeting SARS-CoV-2, such as remdesivir and tilarone.
article
The race to find a coronavirus treatment: are antibodies the answer?
At the beginning of March, US President Donald Trump pressed the pharmaceutical industry to “accelerate the development” of vaccines and therapies to contain the outbreak of the coronavirus pandemic. This article explores what is currently known about COVID-19 and potential treatments that are in the pipeline.
article
Not everyone loves surprises: know your ADC’s critical quality attributes
The importance of product characterisation throughout the entire drug development process cannot be understated. Success, money and lives depend on it. This article delves into why you need to understand every aspect of an ADC in order to prevent unwelcome surprises down the line.
article
In vitro platforms for de-risking nephrotoxicity during drug development
If not correctly assessed, drug candidates with undesirable safety issues may progress through clinical development, resulting in costly failures later in the development process. Given that many drugs fail in clinical trials due to nephrotoxicity, this article describes the importance of understanding kidney transporter function in drug development, how current…
article
Developing an algorithm to predict drug-induced liver injury
A collaboration between Elsevier and the FDA will present an algorithm for the accurate prediction of drug-induced liver injury. Drug Target Review investigates the benefits this toxicology project will bring to the drug discovery industry.
article
Getting precise: how humanised models aid in biologics drug discovery
Humanised immune system (HIS) models have enabled numerous in vivo evaluations of immuno-modulating biologic drugs and ongoing improvements continue to extend their utility. Paul Volden explores the application of HIS models in precision and personalised medicine with a focus on biologics, including how HIS models are used, why they are…
article
Using droplet digital PCR to monitor the safety of CAR T cells
CAR T-cell therapy has caused quite a stir in the immunotherapy world, but it is a process that requires precision and care. Quantitative polymerase chain reaction (qPCR) has thus far been the stalwart technique for providing a check on copy numbers, but here Ping Jin explains why droplet digital PCR…
news
Stephen Hahn nominated to be new FDA commissioner
President Trump has announced his intent to nominate Stephen Hahn as Commissioner of Food and Drugs at the Department of Health and Human Services.
news
Treatment for polycystic kidney disease shows promising results
A potential treatment for polycystic kidney disease has shown positive results in animal testing.
